Thus, neoplasia that presents a high expression of ligands in tumor cells, such as PD-L1, as well as a high rate of tumor-infiltrating CD8+ T cells with high expression of inhibitory ICs are linked with a better response to treatments with ICB [107]. This evidence concerns the gene CD8A and neoplasm.